Straits Times Index
3,306.78 +3.59 (+0.11%) Nikkei
38,751.21 +515.14 (+1.35%) Hang Seng
18,455.14 -123.16 (-0.66%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,311.15 -899.79 (-1.40%) CMC Crypto 200
1,364.53 +51.91 (+3.95%)
GRTX Sep 2024 2.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 2.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 23 |
GlobeNewswireGalera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in res
- GlobeNewswire
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder valueMALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided recent corporate updates. "As a result of last year’s FDA request for a
Simply Wall St.Galera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17
The recent 19% drop in Galera Therapeutics, Inc.'s ( NASDAQ:GRTX ) stock could come as a blow to insiders who purchased...
